ClinicalTrials.gg
CompletedNCT01511367Updated Oct 24, 2018

Comparison of Flutiform, Fluticasone and Seretide in Treatment of Moderate to Severe Asthma in Paediatric Patients

A Phase 3 interventional study of Flutiform and Seretide in Asthma, sponsored by Mundipharma Research Limited. Completed at 8 sites in 8 countries. Open to participants aged 5 Years to 12 Years. Per ClinicalTrials.gov, last updated 2018-10-24.

Sponsored by Mundipharma Research Limited (part of Mundipharma) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
498
Allocation
Randomized
Ages
5 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.

Planned enrollment
30th of 146
498 · median 100
Started
2012
with 12 others
Phase 3
35 of 147
none open now
Registered
85th of 147
by date
Lead sponsor
2 of 147
Mundipharma Research Limited

Among the 147 studies testing fluticasone in Asthma, this one is the 30th largest by planned enrollment of the 146 interventional ones that give a count, is one of 13 that started in 2012, is one of 35 in phase 3, and was the 85th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 5 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies testing fluticasone in Asthma, or all of them as a file.
02

Study summary

This is a comparator study to assess safety and efficacy of Flutiform compared with Fluticasone pMDI and Seretide pMDI in paediatric asthma patients with moderate to severe persistent, reversible asthma.

Read the detailed description

This is a study involving a 2-4 week run-in phase followed by a 12 week double blind treatment phase. During the run-in phase, all subjects receive Flixotide. In the treatment phase subjects will be randomised to one of the 3 treatment groups and will receive active Flutiform and placebo Flixotide or Active Seretide and placebo Flixotide or active Flixotide and either placebo seretide or placebo Flutiform. Efficacy will be assessed by lung function tests, asthma symptoms, sleep disturbance due to asthma and rescue medication use. Safety will be assessed by adverse events, lab tests, urinary cortisol and vital signs.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • moderate to severe persistent reversible asthma
04

Who can participate

Ages eligible
5 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and Female subjects 5 to \<12 years old.
  2. Known history of moderate to severe persistent reversible asthma1 for ≥ 6 months prior to the screening visit.
  3. Demonstrated of ≥ 60% to ≤ 90% for predicted normal values (Polgar 1971) during the screening period following appropriate withholding of asthma medications (if applicable):

    • No LABA use within 12 hours and/or no SABA use within 6 hours of the PFT
    • No use of inhaled ICS-LABA asthma therapy within 12 hours of the PFT
    • Inhaled are allowed on the day of screening
  4. Documented reversibility of ≥ 15% in FEV1 in the screening period
  5. Current use of an inhaled corticosteroid for asthma at a stable dose for at least 4 weeks prior to the screening visit
  6. Inadequate asthma control on an ICS alone at a dose of ≤ 500 µg fluticasone equivalents/day, OR controlled asthma on an ICS-LABA combination at a ICS dose of ≤ 200 µg fluticasone equivalents/day
  7. Demonstrated satisfactory technique in the use of the pMDI and spacer device
  8. Can perform spirometry adequately
  9. Willing and able to enter information in the electronic diary with the help of a parent or guardian, if necessary and attend all study visits
  10. Willing and able to substitute pre-study prescribed inhaled asthma medication for the entire duration of the study
  11. If a female subject is post menarche a urine pregnancy test may be undertaken at the discretion of the investigator and the subjects' parent(s) /legal representative. This test must be negative.
  12. Written and assent obtained as per national law

Exclusion criteria

Exclusion Criteria

  1. Near fatal or life-threatening (including intubation) asthma within the past year
  2. Hospitalisation or an emergency visit for asthma within the past 6 months
  3. History of systemic (injectable or oral) medication within 1 month of the screening visit
  4. Current or prior non-response or partial response only to an ICS-LABA combination1
  5. Evidence of a clinically unstable disease, as determined by medical history, clinical laboratory tests, and physical examination that, in the Investigator's opinion, preclude entry into the study. "" is defined as any disease that, in the opinion of the Investigator, would put the subject at risk through study participation, or which would affect the outcome of the study
  6. In the Investigator's opinion a clinically significant upper or lower respiratory infection within 4 weeks prior to the screening visit
  7. Significant, non-reversible active pulmonary disease (e.g. cystic fibrosis, bronchiecstasis, tuberculosis)
  8. Known (HIV)-positive status
  9. Current smoking history within 12 months prior to the screening visit
  10. Current evidence of alcohol or substance abuse within 12 months prior to the screening visit
  11. Subjects who have taken β- blocking agents, tricyclic antidepressants, monoamine oxidase inhibitors, astemizole (Hismanal), quinidine type antiarrythmics, or potent CYP 3A4 inhibitors such as ketoconazole within 1 week prior to the screening visit
  12. Current use of medications, other than those allowed in the protocol, that in the investigator's opinion will have an effect on bronchospasm and/or pulmonary function
  13. Current evidence of or idiosyncratic reaction to test medications or components
  14. Receipt of an medicinal product within 30 days of the screening visit
  15. Current participation in a clinical study
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
498 participants (estimated)

Study arms

  • Active comparator
    Flutiform

    Drug: Flutiform

  • Active comparator
    Seretide

    Drug: Seretide

  • Active comparator
    Flixotide

    Drug: Flixotide

Interventions

  • 50/5ug (fluticasone/formoterol) 2 puffs twice daily

  • DrugSeretide

    50/25 ug (fluticasone/salmeterol) 2 puffs twice daily

  • 50ug 2 puffs twice daily

06

What researchers measure

Primary outcomes

  1. To show superiority in the efficacy of Flutiform pMDI 50/5μg (2 puffs bid) versus fluticasone pMDI 50 μg (2 puffs bid).

    Change from pre-dose Forced Expiratory Volume in one second (FEV1) in litres at baseline to 2 hours post-dose FEV1 at the end of the 12 week treatment period.

    Time frame: 12 weeks

Secondary outcomes

  1. Show non-inferiority in the efficacy of Flutiform to Seretide

    Change from pre-dose FEV1 at baseline to 2 hours post-dose FEV1 at Day 1 and FEV1 AUC0-4 at Day 1 and Week 12 (Flutiform vs Seretide)

    Time frame: 12 weeks

07

Study locations

8 sites
  • Plovdiv, Bulgaria
  • Alergologie Skopkova s.r.o
    Ostrava-Marianske Hory, Czechia
  • Illés és Ádám Egészségügyi Szolgáltató Bt.
    Kiskunhalas, Hungary
  • New Dehli, India
  • Alergo-Med Specjalistyczna Przychodnia Lekarska Sp.z.o.o.
    Tarnow, Poland
  • Spitalul Judetean de Urgenta Deva
    Deva, Hunedoara, Romania
  • Moscow, Russian Federation
  • Odessa, Ukraine
08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2012, a primary completion of Sep 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2011
First posted
Jan 18, 2012
Start
Mar 2012
Primary completionActual
Sep 2013
CompletionActual
Nov 2013
Last update
Oct 24, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01511367
Responsible party
Sponsor
First posted
Jan 18, 2012
Start date
Mar 2012
Primary completion
Sep 2013
Completion
Nov 2013
Last update
Oct 24, 2018
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluticasone-formoterol · Fluticasone

Start the discussion